To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways

Completed · Phase 3 · Has a placebo group

Conditions studied: Pulmonary Disease, Chronic Obstructive

In brief

The primary objectives of the study are to explore the effect of treatment with orally inhaled tiotropium + olodaterol fixed dose combination with and without exercise training, and tiotropium comparing to placebo, on top of behavioural modification in improving exercise capacity in patients with COPD

Key facts

Study ID

NCT02085161

Run by

Boehringer Ingelheim

People needed

304

Starts

2014-03-01

Expected to finish

2015-10-01

Last updated by the study team

2017-01-06

Who can join

Age: 40 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All patients must sign an informed consent consistent with International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) - Good Clinical Practice (GCP) guidelines prior to participation in the trial, which includes medication washout and restrictions.
• All patients must have a diagnosis of chronic obstructive pulmonary disease and must meet the following spirometric criteria: Patients must have relatively stable airway obstruction with a post-bronchodilator forced expiratory volume in one second >=30% and <80% of predicted normal; Global Initiative for Chronic Obstructive Lung Disease grade II - III, and a post-bronchodilator Tiffeneau index <70% at Visit 1.
• Male or female patients, aged >=40 years and <=75 years.
• Patients must be current or ex-smokers with a smoking history of more than 10 pack years. Patients who have never smoked cigarettes must be excluded.

You may not qualify if…

• Patients with a significant disease other than chronic obstructive pulmonary disease.
• Patients with clinically relevant abnormal baseline haematology, blood chemistry, or urinalysis.
• Patients with a history of asthma.
• A diagnosis of thyrotoxicosis.
• A diagnosis of paroxysmal tachycardia (>100 beats per minute).
• A history of myocardial infarction within 1 year of screening visit.
• Unstable or life-threatening cardiac arrhythmia.
• Hospitalized for heart failure within the past year.
• Known active tuberculosis.
• A malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years.
• A history of life-threatening pulmonary obstruction and patients with chronic respiratory failure.
• A history of cystic fibrosis.
• Clinically evident bronchiectasis.
• A history of significant alcohol or drug abuse.
• Any contraindications for exercise testing.
• Patients who have undergone thoracotomy with pulmonary resection.
• Patients being treated with any oral ß-adrenergics.
• Patients being treated with oral corticosteroid medication at unstable doses (i.e., less than six weeks on a stable dose) or at doses in excess of the equivalent of 10 mg of prednisone per day or 20 mg every other day.
• Patients who regularly use daytime oxygen therapy for more than one hour per day and in the investigators opinion will be unable to abstain from the use of oxygen therapy during clinic visits.
• Patients who have completed a pulmonary rehabilitation program in the six weeks prior to the screening visit or patients who are currently in a pulmonary rehabilitation program.
• Patients who have a limitation of exercise performance as a result of factors other than fatigue or exertional dyspnoea, such as arthritis in the leg, angina pectoris or claudication or morbid obesity.
• Patients who have taken an investigational drug within one month or six half lives (whichever is greater) prior to screening visit.
• Patients with known hypersensitivity to ß-adrenergics drugs, anticholinergic drugs, benzalkonium chloride, disodium edentat, or any other component of the Respimat® inhalation solution delivery system.
• Pregnant or nursing women.
• Women of childbearing potential not using highly effective methods of birth control.

Where it is running

• Boehringer Ingelheim Investigational Site — San Diego, California, United States
• Boehringer Ingelheim Investigational Site — Torrance, California, United States
• Boehringer Ingelheim Investigational Site — Hartford, Connecticut, United States
• Boehringer Ingelheim Investigational Site — Daw Park, South Australia, Australia
• Boehringer Ingelheim Investigational Site — Glen Osmond, South Australia, Australia
• Boehringer Ingelheim Investigational Site — Salzburg, Austria
• Boehringer Ingelheim Investigational Site — Genk, Belgium
• Boehringer Ingelheim Investigational Site — Hasselt, Belgium
• Boehringer Ingelheim Investigational Site — Leuven, Belgium
• Boehringer Ingelheim Investigational Site — Montreal, Quebec, Canada
• Boehringer Ingelheim Investigational Site — Ste-Foy, Quebec, Canada
• Boehringer Ingelheim Investigational Site — Saskatoon, Saskatchewan, Canada
• Boehringer Ingelheim Investigational Site — Kolding, Denmark
• Boehringer Ingelheim Investigational Site — København NV, Denmark
• Boehringer Ingelheim Investigational Site — Odense, Denmark
• Boehringer Ingelheim Investigational Site — Berlin, Germany
• Boehringer Ingelheim Investigational Site — Bochum, Germany
• Boehringer Ingelheim Investigational Site — Frankfurt, Germany
• Boehringer Ingelheim Investigational Site — Großhansdorf, Germany
• Boehringer Ingelheim Investigational Site — Heidelberg, Germany
• Boehringer Ingelheim Investigational Site — Leverkusen, Germany
• Boehringer Ingelheim Investigational Site — Solingen, Germany
• Boehringer Ingelheim Investigational Site — Teuchern, Germany
• Boehringer Ingelheim Investigational Site — Tübingen, Germany
• Boehringer Ingelheim Investigational Site — Greenlane East Auckland NZ, New Zealand

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.